Richard Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard Hall has a total of 293 co-authors. Here are the top co-authors by number of shared publications:
Alexis F. Turgeon
Université Laval, Quebec City, QC, Canada
4 shared publications- Derek Jason Roberts
University of Ottawa
3 shared publications - Gregory Lyle Bryson
Centre for Journalology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
3 shared publications Agnieszka Grabowski-Comeau
Dalhousie University and the Capital District Health Authority
2 shared publicationsAndré Denault
Université de Montréal, Montréal, QC, Canada
2 shared publicationsC. David Mazer
St. Michael's Hospital, Toronto, ON, Canada
2 shared publications
Latest Publications
- 1 June 2021
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 35 (6) , 1813-1820
Survey of the Preparation of Cardiovascular Emergency Medications for Adult Cardiovascular Anesthesia
- 1 June 2021
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 35 (6) , 1813-1820
Survey of the Preparation of Cardiovascular Emergency Medications for Adult Cardiovascular Anesthesia
- Open Access
- 3 September 2020
- Published by American Society for Engineering Education
- p. 7.65.1-7.65.11
A Model For The Evaluation Of Innovative Engineering Courseware: Engineering An Assessment Program
- 3 September 2020
- Published by American Society for Engineering Education
- p. 7.65.1-7.65.11
Open AccessA Model For The Evaluation Of Innovative Engineering Courseware: Engineering An Assessment Program
- Open Access
- 3 September 2020
- Published by American Society for Engineering Education
- p. 7.656.1-7.656.10
Incorporating Web Based Homework Problems In Engineering Dynamics
- 3 September 2020
- Published by American Society for Engineering Education
- p. 7.656.1-7.656.10
Open AccessIncorporating Web Based Homework Problems In Engineering Dynamics
- 1 December 2019
- Published by Elsevier in Anesthesiology Clinics
- Vol. 37 (4) , 787-800
Cardiac Surgery and the Blood-Brain Barrier
- 1 December 2019
- Published by Elsevier in Anesthesiology Clinics
- Vol. 37 (4) , 787-800
Cardiac Surgery and the Blood-Brain Barrier
- 14 July 2017
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (10) , 1009-1022
An observational study examining the effects of a surgically induced inflammatory response on the distribution of morphine and its metabolites into cerebrospinal fluid
Purpose Morphine is administered intravenously for pain management in the perioperative period. The effect of the inflammatory response to surgery on morphine distribution across the blood-brain barrier (BBB) in humans was investigated. We hypothesized that a graded surgically induced, systemic inflammatory response alters cerebrospinal fluid (CSF) levels of morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) through a temporary reduction in BBB drug efflux transporter function. Methods We conducted a prospective pharmacokinetic study of the plasma and CSF distribution of the P-glycoprotein (PGP) substrate morphine in 33 patients undergoing open thoracic (n = 18) or endovascular (n = 15) aortic aneurysm repair. Morphine was administered with induction of anesthesia and in the intensive care unit. Plasma and CSF concentrations of interleukin (IL)-6, morphine, M3G, M6G, and albumin were measured prior to surgery (baseline), during surgery, and postoperatively every six hours until removal of the CSF drain. The area under the curve (AUC) was determined for plasma and CSF IL-6, morphine, M3G, and M6G concentrations vs time. The primary endpoint measures were the correlations between the morphine, M6G, and M3G AUC CSF/plasma ratios and systemic inflammation as quantified by the time-normalized IL-6 exposure, which was calculated for each individual by dividing the total exposure (AUC) by time (t). A Bonferroni corrected P < 0.017 indicated a significant correlation. Results Plasma and CSF IL-6 concentrations increased postoperatively. The median [interquartile range] IL-6 exposures were significantly higher in the open vs endovascular surgical group for plasma (105 [40-256] pg·mL−1 vs 29 [16-70] pg·mL−1, respectively; P = 0.013) and CSF (79 [26-133] pg·mL−1 vs 16 [9-80] pg·mL−1, respectively; P = 0.013). For the primary endpoint, the plasma IL-6 AUC/t did not correlate with the CSF accumulation of morphine (r = −0.009; P = 0.96) or M3G (r = 0.37; P = 0.04) when corrected for surgical procedure, age, and sex. There were insufficient data on CSF concentration to complete the primary analysis for M6G. Conclusion Morphine distribution into the CSF was not significantly altered in patients undergoing thoracic aortic aneurysm repair. This suggests that BBB PGP function may not be affected by the perioperative inflammatory response. Trial registration www.clinicaltrials.gov, NCT 00878371. Registered 7 April 2009.
- 14 July 2017
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (10) , 1009-1022
An observational study examining the effects of a surgically induced inflammatory response on the distribution of morphine and its metabolites into cerebrospinal fluid
Purpose Morphine is administered intravenously for pain management in the perioperative period. The effect of the inflammatory response to surgery on morphine distribution across the blood-brain barrier (BBB) in humans was investigated. We hypothesized that a graded surgically induced, systemic inflammatory response alters cerebrospinal fluid (CSF) levels of morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) through a temporary reduction in BBB drug efflux transporter function. Methods We conducted a prospective pharmacokinetic study of the plasma and CSF distribution of the P-glycoprotein (PGP) substrate morphine in 33 patients undergoing open thoracic (n = 18) or endovascular (n = 15) aortic aneurysm repair. Morphine was administered with induction of anesthesia and in the intensive care unit. Plasma and CSF concentrations of interleukin (IL)-6, morphine, M3G, M6G, and albumin were measured prior to surgery (baseline), during surgery, and postoperatively every six hours until removal of the CSF drain. The area under the curve (AUC) was determined for plasma and CSF IL-6, morphine, M3G, and M6G concentrations vs time. The primary endpoint measures were the correlations between the morphine, M6G, and M3G AUC CSF/plasma ratios and systemic inflammation as quantified by the time-normalized IL-6 exposure, which was calculated for each individual by dividing the total exposure (AUC) by time (t). A Bonferroni corrected P < 0.017 indicated a significant correlation. Results Plasma and CSF IL-6 concentrations increased postoperatively. The median [interquartile range] IL-6 exposures were significantly higher in the open vs endovascular surgical group for plasma (105 [40-256] pg·mL−1 vs 29 [16-70] pg·mL−1, respectively; P = 0.013) and CSF (79 [26-133] pg·mL−1 vs 16 [9-80] pg·mL−1, respectively; P = 0.013). For the primary endpoint, the plasma IL-6 AUC/t did not correlate with the CSF accumulation of morphine (r = −0.009; P = 0.96) or M3G (r = 0.37; P = 0.04) when corrected for surgical procedure, age, and sex. There were insufficient data on CSF concentration to complete the primary analysis for M6G. Conclusion Morphine distribution into the CSF was not significantly altered in patients undergoing thoracic aortic aneurysm repair. This suggests that BBB PGP function may not be affected by the perioperative inflammatory response. Trial registration www.clinicaltrials.gov, NCT 00878371. Registered 7 April 2009.
- 1 April 2017
- Published by Elsevier in Journal of Critical Care
- Vol. 40, 272
Global research preparedness for outbreak-related critical illness
- 1 April 2017
- Published by Elsevier in Journal of Critical Care
- Vol. 40, 272
Global research preparedness for outbreak-related critical illness
- 17 October 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (1) , 45-64
Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review
Knowledge of how alterations in pharmacogenomics and pharmacogenetics may affect drug therapy in the intensive care unit (ICU) has received little study. We review the clinically relevant application of pharmacogenetics and pharmacogenomics to drugs and conditions encountered in the ICU. We selected relevant literature to illustrate the important concepts contained within. Two main approaches have been used to identify genetic abnormalities - the candidate gene approach and the genome-wide approach. Genetic variability in response to drugs may occur as a result of alterations of drug-metabolizing (cytochrome P [CYP]) enzymes, receptors, and transport proteins leading to enhancement or delay in the therapeutic response. Of relevance to the ICU, genetic variation in CYP-450 isoenzymes results in altered effects of midazolam, fentanyl, morphine, codeine, phenytoin, clopidogrel, warfarin, carvedilol, metoprolol, HMG-CoA reductase inhibitors, calcineurin inhibitors, non-steroidal anti-inflammatory agents, proton pump inhibitors, and ondansetron. Changes in cholinesterase enzyme function may affect the disposition of succinylcholine, benzylisoquinoline muscle relaxants, remifentanil, and hydralazine. Genetic variation in transport proteins leads to differences in the response to opioids and clopidogrel. Polymorphisms in drug receptors result in altered effects of β-blockers, catecholamines, antipsychotic agents, and opioids. Genetic variation also contributes to the diversity and incidence of diseases and conditions such as sepsis, malignant hyperthermia, drug-induced hypersensitivity reactions, cardiac channelopathies, thromboembolic disease, and congestive heart failure. Application of pharmacogenetics and pharmacogenomics has seen improvements in drug therapy. Ongoing study and incorporation of these concepts into clinical decision making in the ICU has the potential to affect patient outcomes.
- 17 October 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 64 (1) , 45-64
Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review
Knowledge of how alterations in pharmacogenomics and pharmacogenetics may affect drug therapy in the intensive care unit (ICU) has received little study. We review the clinically relevant application of pharmacogenetics and pharmacogenomics to drugs and conditions encountered in the ICU. We selected relevant literature to illustrate the important concepts contained within. Two main approaches have been used to identify genetic abnormalities - the candidate gene approach and the genome-wide approach. Genetic variability in response to drugs may occur as a result of alterations of drug-metabolizing (cytochrome P [CYP]) enzymes, receptors, and transport proteins leading to enhancement or delay in the therapeutic response. Of relevance to the ICU, genetic variation in CYP-450 isoenzymes results in altered effects of midazolam, fentanyl, morphine, codeine, phenytoin, clopidogrel, warfarin, carvedilol, metoprolol, HMG-CoA reductase inhibitors, calcineurin inhibitors, non-steroidal anti-inflammatory agents, proton pump inhibitors, and ondansetron. Changes in cholinesterase enzyme function may affect the disposition of succinylcholine, benzylisoquinoline muscle relaxants, remifentanil, and hydralazine. Genetic variation in transport proteins leads to differences in the response to opioids and clopidogrel. Polymorphisms in drug receptors result in altered effects of β-blockers, catecholamines, antipsychotic agents, and opioids. Genetic variation also contributes to the diversity and incidence of diseases and conditions such as sepsis, malignant hyperthermia, drug-induced hypersensitivity reactions, cardiac channelopathies, thromboembolic disease, and congestive heart failure. Application of pharmacogenetics and pharmacogenomics has seen improvements in drug therapy. Ongoing study and incorporation of these concepts into clinical decision making in the ICU has the potential to affect patient outcomes.
- 24 August 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 63 (11) , 1215-1222
Can we create a Canadian Perioperative Anesthesia Clinical Trials Group? We review the first five years and glimpse into the future
- 24 August 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 63 (11) , 1215-1222
Can we create a Canadian Perioperative Anesthesia Clinical Trials Group? We review the first five years and glimpse into the future
- 19 July 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 63 (9) , 1116
Erratum to: Should ancillary brain blood flow analyses play a larger role in the neurological determination of death?
- 19 July 2016
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 63 (9) , 1116
Erratum to: Should ancillary brain blood flow analyses play a larger role in the neurological determination of death?